LYSMD2

Across TCGA pan-cancer cohorts, LYSMD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYSMD2 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LYSMD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LYSMD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where LYSMD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.900	1.000	.010	18	view →
PDAC	OS	Median	All	0.560	0.296	.003	16	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.877	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LYSMD2–CCRCC (OS)

Open the CCRCC breakdown →